37 Million Americans Have Kidney Disease—Here's What New 2026 Medications Can Actually Do

New medications approved in 2026 are transforming how doctors treat chronic kidney disease (CKD), offering hope to the 37 million American adults living with this condition. These breakthrough treatments focus on slowing disease progression, reducing protein in urine, and lowering cardiovascular risk through five main drug categories that work directly through the kidneys to reduce pressure and inflammation.

What Are SGLT2 Inhibitors and How Do They Help Kidneys?

Sodium-Glucose-Cotransporter 2 (SGLT2) inhibitors represent one of the most promising categories of new kidney medications. These oral drugs work by preventing the kidneys from reabsorbing sugar back into the body, which reduces pressure in both the kidneys and heart. Patients often experience additional benefits like weight loss and lower blood pressure.

The newest SGLT2 inhibitors approved for kidney protection include:

• Farxiga (Dapagliflozin): Reduces kidney and heart pressure by blocking sugar reabsorption, though common side effects include yeast infections and urinary tract infections
• Jardiance (Empagliflozin): Helps kidneys remove excess sugar and salt through urine and can be used by all kidney patients, whether they have diabetes or not
• Invokana (Canagliflozin): Lowers blood sugar and reduces strain on kidneys and heart by blocking SGLT2, but isn't recommended for patients with severe kidney problems
• Steglatro (Ertugliflozin): Removes excess sugar through urine but shows little effect on heart disease in clinical trials
• Brenzavvy (Bexagliflozin): Specifically designed for patients with type 2 diabetes to reduce excess sugar through kidney filtration

How Effective Are GLP-1 Agonists for Kidney Protection?

GLP-1 agonists, originally developed for diabetes and weight loss, are showing remarkable kidney-protective benefits. These powerful medications slow disease progression, reduce inflammation, lower blood pressure, and decrease protein in urine while improving heart health in patients with type 2 diabetes and chronic kidney disease.

Ozempic or Wegovy (Semaglutide) represents a significant development for kidney health, showing a 24% lower risk of major kidney events in large clinical trials. Mounjaro or Zepbound (Tirzepatide) can slow the decline of kidney function and reduce protein in urine, with trials showing it lowered the risk of major kidney issues including estimated glomerular filtration rate (eGFR) decline, renal death, and progression to end-stage kidney disease.

What Other Medication Categories Protect Kidneys?

Beyond SGLT2 inhibitors and GLP-1 agonists, three additional drug categories are proving essential for kidney protection. Angiotensin-Converting Enzyme (ACE) inhibitors like Vasotec, Zestril, and Altace work by relaxing and widening blood vessels, which lowers blood pressure and reduces strain on both the heart and kidneys. These medications help kidneys by removing salt and water, with some like Vasotec specifically slowing the progression of diabetic nephropathy.

Angiotensin Receptor Blockers (ARBs) serve as alternatives when patients can't tolerate ACE inhibitors. Medications like Cozaar (Losartan) and Diovan (Valsartan) significantly decrease protein in urine—a key sign of kidney damage—and can delay the need for dialysis in patients with advanced chronic kidney disease. Mineralocorticoid Receptor Antagonists (MRAs) like Aldactone and the newer Kerendia (Finerenone) block the hormone aldosterone, reducing inflammation and fibrosis to protect kidney tissue.

All these medications require regular blood test monitoring to track kidney function, and patients must be cautious with over-the-counter drugs like Advil and Aleve that can increase kidney damage. The goal remains consistent across all categories: slowing disease progression, managing symptoms, and preventing serious complications like heart attack or stroke while protecting remaining kidney function.